Novo Nordisk Targets 'Obesity Disease Market' Despite Commercial Doubts
Executive Summary
Novo Nordisk is targeting obesity as a key disease market, but its CEO says global alliances are needed in future to help fight the global pandemic, including the food industry.
You may also be interested in...
"Synergy Search" Lies Behind AZ's Combined CV, Diabetes and Renal Ops
The head of AstraZeneca's newly combined cardiovascular, metabolic diseases and renal franchise says his mission is to align and find synergies for the three therapeutic areas.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.